167 related articles for article (PubMed ID: 22904129)
21. Risk factors for urothelial carcinoma of the prostate in patients undergoing radical cystoprostatectomy for bladder cancer.
Patel SG; Cookson MS; Barocas DA; Clark PE; Smith JA; Chang SS
BJU Int; 2009 Oct; 104(7):934-7. PubMed ID: 19338554
[TBL] [Abstract][Full Text] [Related]
22. Immunophenotypic characterization of 225 prostate adenocarcinomas with intermediate or high Gleason scores.
Goldstein NS
Am J Clin Pathol; 2002 Mar; 117(3):471-7. PubMed ID: 11888088
[TBL] [Abstract][Full Text] [Related]
23. Urothelial and incidental prostate carcinoma in prostates from cystoprostatectomies for bladder cancer: is there a relationship between urothelial and prostate cancer?
Barbisan F; Mazzucchelli R; Scarpelli M; Lopez-Beltran A; Cheng L; Kirkali Z; Montironi R
BJU Int; 2009 Apr; 103(8):1058-63. PubMed ID: 19076141
[TBL] [Abstract][Full Text] [Related]
24. The pagetoid variant of bladder urothelial carcinoma in situ A clinicopathological study of 11 cases.
Lopez-Beltran A; Luque RJ; Moreno A; Bollito E; Carmona E; Montironi R
Virchows Arch; 2002 Aug; 441(2):148-53. PubMed ID: 12189504
[TBL] [Abstract][Full Text] [Related]
25. Diagnostic utility of androgen receptor expression in discriminating poorly differentiated urothelial and prostate carcinoma.
Downes MR; Torlakovic EE; Aldaoud N; Zlotta AR; Evans AJ; van der Kwast TH
J Clin Pathol; 2013 Sep; 66(9):779-86. PubMed ID: 23775437
[TBL] [Abstract][Full Text] [Related]
26. Urothelial carcinoma involving the gynecologic tract: a morphologic and immunohistochemical study of 6 cases.
Reyes MC; Park KJ; Lin O; Ioffe O; Isacson C; Soslow RA; Reuter VE; Fine SW
Am J Surg Pathol; 2012 Jul; 36(7):1058-65. PubMed ID: 22510759
[TBL] [Abstract][Full Text] [Related]
27. Utility of p63 and high molecular weight cytokeratin in the distinction between urothelial carcinoma with prostatic stromal invasion and urothelial carcinoma with colonisation of prostatic ducts and acini.
Chastain EC; Oliva IV; Osunkoya AO
Pathology; 2012 Apr; 44(3):199-203. PubMed ID: 22406481
[TBL] [Abstract][Full Text] [Related]
28. Immunohistochemistry of cytokeratin (CK) 5/6, CD44 and CK20 as prognostic biomarkers of non-muscle-invasive papillary upper tract urothelial carcinoma.
Jung M; Kim B; Moon KC
Histopathology; 2019 Feb; 74(3):483-493. PubMed ID: 30286252
[TBL] [Abstract][Full Text] [Related]
29. Association of current molecular subtypes in urothelial carcinoma with patterns of muscularis propria invasion.
Haghayeghi K; Lu S; Matoso A; Schiff SF; Mueller-Leonhard C; Amin A
Virchows Arch; 2021 Sep; 479(3):515-521. PubMed ID: 34218288
[TBL] [Abstract][Full Text] [Related]
30. Value of P63 and CK5/6 in distinguishing squamous cell carcinoma from adenocarcinoma in lung fine-needle aspiration specimens.
Khayyata S; Yun S; Pasha T; Jian B; McGrath C; Yu G; Gupta P; Baloch Z
Diagn Cytopathol; 2009 Mar; 37(3):178-83. PubMed ID: 19170169
[TBL] [Abstract][Full Text] [Related]
31. Immunohistochemical expression of CK20, p53, and Ki-67 as objective markers of urothelial dysplasia.
Mallofré C; Castillo M; Morente V; Solé M
Mod Pathol; 2003 Mar; 16(3):187-91. PubMed ID: 12640096
[TBL] [Abstract][Full Text] [Related]
32. Subclassification of non-small cell lung carcinomas lacking morphologic differentiation on biopsy specimens: Utility of an immunohistochemical panel containing TTF-1, napsin A, p63, and CK5/6.
Mukhopadhyay S; Katzenstein AL
Am J Surg Pathol; 2011 Jan; 35(1):15-25. PubMed ID: 21164283
[TBL] [Abstract][Full Text] [Related]
33. Poorly differentiated adenocarcinomas of prostate versus high-grade urothelial carcinoma of the bladder: a diagnostic dilemma with immunohistochemical evaluation of 2 cases.
Martínez-Rodríguez M; Ramos D; Soriano P; Subramaniam M; Navarro S; Llombart-Bosch A
Int J Surg Pathol; 2007 Apr; 15(2):213-8. PubMed ID: 17478786
[TBL] [Abstract][Full Text] [Related]
34. [Immunohistochemic staining for CK5/6 and P63 significance in prostate premalignant lesions and adenocarcinoma].
Marin LV; Ferariu D; Mihailovici MS
Rev Med Chir Soc Med Nat Iasi; 2010; 114(3):818-22. PubMed ID: 21243809
[TBL] [Abstract][Full Text] [Related]
35. Molecular pathways of urothelial development and bladder tumorigenesis.
Castillo-Martin M; Domingo-Domenech J; Karni-Schmidt O; Matos T; Cordon-Cardo C
Urol Oncol; 2010; 28(4):401-8. PubMed ID: 20610278
[TBL] [Abstract][Full Text] [Related]
36. [Metastatic lymph node collision of a prostatic adenocarcinoma and an urothelial carcinoma and review of the literature].
Junca A; Frouin E; Irani J; Fromont G; Levillain P
Ann Pathol; 2015 Dec; 35(6):496-501. PubMed ID: 26597142
[TBL] [Abstract][Full Text] [Related]
37. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.
Khalifeh IM; Albarracin C; Diaz LK; Symmans FW; Edgerton ME; Hwang RF; Sneige N
Am J Surg Pathol; 2008 Apr; 32(4):544-52. PubMed ID: 18300793
[TBL] [Abstract][Full Text] [Related]
38. [Prostatic urothelial location of a tumor of the bladder].
Coulange C; Lechevallier E; de Fromont M
Prog Urol; 1997 Feb; 7(1):128-31. PubMed ID: 9116731
[TBL] [Abstract][Full Text] [Related]
39. Predicting outcomes in non-muscle invasive (Ta/T1) bladder cancer: the role of molecular grade based on luminal/basal phenotype.
Rebola J; Aguiar P; Blanca A; Montironi R; Cimadamore A; Cheng L; Henriques V; Lobato-Faria P; Lopez-Beltran A
Virchows Arch; 2019 Oct; 475(4):445-455. PubMed ID: 31240474
[TBL] [Abstract][Full Text] [Related]
40. [Carcinoma in situ of the bladder involving the prostate with an unusual invasive pattern following BCG therapy: a case report].
Iba A; Kohjimoto Y; Inagaki T; Suzuki A; Fujii R; Senzaki H; Uekado Y; Shinka T
Hinyokika Kiyo; 2005 Oct; 51(10):681-4. PubMed ID: 16285623
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
